Market+ (iPhone)

Market+ (Android)

US STOCKS

FUNDS

FX & CRYPTO

SH/SZ-HK

HK STOCKS

IPO Plus - IPO

To-be Listed

	Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
No Upcoming IPO

Summary

We are a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since our inception in 2001, we have focused on human medicine and have established technology platforms with our understanding of immunology and protein engineering, which empowers us to develop our recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability. As of the Latest Practicable Date, our product pipeline consisted of three clinical-stage product candidates, including our Core Product LZ901, and four pre-clinical-stage product candidates. As of the same date, we had two invention patents and seven pending applications relating to our Core Product. All of the registered patents and patent applications for our Core Product are related to the same set of patent claims filed to nine different jurisdictions to protect our intellectual property, given that in addition to China and the U.S., the other jurisdictions are also the target markets or potential markets in the future for LZ901. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CORE PRODUCT, OR ANY OF OUR PIPELINE PRODUCTS. Since our inception, we have strategically focused on internally developing innovative human vaccines, including bacterial-based vaccines and recombinant vaccines, and therapeutic biologics, such as monoclonal antibodies and bispecific antibodies, targeting a broad spectrum of infectious diseases, cancer, and autoimmune diseases. Leveraging our technology platforms and strong research and development capabilities, we established a diversified and advanced product pipeline. During the Track Record Period and up to the Latest Practicable Date, we did not generate any revenue as we had out-licensed most of our historically developed candidates before the Track Record Period, and by the Latest Practicable Date we had not commercialized any of our product candidates. OUR BUSINESS MODEL We operate a business model focused on in-house discovery, research and development and commercialization, and out-licensing of high-quality and affordable human vaccines and therapeutic biologics. We are led by an experienced management team that manages our research and development, manufacturing and commercialization. Our co-founder, executive Director, general manager and chief scientist, Mr. KONG Jian, has over 33 years of biopharmaceutical experience leading scientific research of biological products and has developed five bacteria vaccines (the “Bacteria Vaccines”). For details, please see “— Our Products and Product Candidates — Our Other Historically Developed Products” and “Business — Our Products and Product Candidates — Our Commercialized Vaccine Products” in this document. Led by our management team and supported by our research and development team with strong execution capabilities, we have adopted an efficient approach to identify proven targets, such as antigens, that have produced effects during treatment to optimize, transform and develop into product candidates that enhance our portfolio for the treatment of cancer and autoimmune diseases. We have built a diversified and advanced product pipeline. We expect to continue to advance our pipeline of clinical-stage and pre-clinical stage product candidates and discover new product candidates over time. Since our inception in 2001 and prior to the Series A Financing in 2019, we primarily relied on (i) capital injections from our shareholders, primarily due to which our registered capital increased from RMB0.5 million in 2001 to RMB78.6 million in 2019, (ii) one-off or milestone payments of RMB34.8 million in total received from our historically developed products that had been transferred or out-licensed to third-parties prior to the Track Record Period, and (iii) revenue generated from the sales of the Immunoreagent Testing Kits to support our business operations, which amounted to RMB9.1 million from 2004 to 2018. For details of the our registered capital and subsequent capital injections by our shareholders since our inception and prior to the Series A Financing, please see the section headed “History, Development and Corporate Structure” in this document. For details of the revenue generated from the sales of the Immunoreagent Testing Kits, please see “— Our Products and Product Candidates — Our Other Historically Developed Products” in this section. In the future, we plan to prioritize the development of innovative recombinant protein vaccines, followed by innovative biological products to meet the unmet needs of disease prevention and treatment. Other than K3, a biosimilar of adalimumab, we do not plan to develop or commercialize any other biosimilars as biosimilars have low profit margins due to fierce competition from originator drugs and other competing biosimilars and the development and commercialization of K3 requires strict cost controls to maintain profit margin. As a result, we plan to focus on innovative recombinant protein vaccines and innovative biological products that have higher profit margins. K3 is the only biosimilar we plan to develop and commercialize as adalimumab holds the largest market share of anti-TNF-α biologics globally and has large market opportunity. Going forward, we will actively explore collaboration opportunities in the development, manufacturing and sales of our products, including out-licensing of our product candidates. We currently do not have any plan to out-license LZ901 and our other product candidates in China. We plan to collaborate with multinational pharmaceutical companies who have a robust sales and marketing network to rapidly commercialize LZ901 globally in overseas markets, including in the U.S. and Southeast Asian countries. As of the Latest Practicable Date, we had only initiated preliminary discussions with third parties to explore opportunities to out-license LZ901 in markets outside of China, and had not identified any collaboration partners. For details, please see “Business — Commercialization” in this document. Before deciding whether to out-license a product candidate, we identify collaboration partners who may be better positioned to accelerate or further research and development or successful commercialization of the product candidate. We communicate with our collaboration partners, approximately once a quarter and on an irregular basis for related technologies for Beijing Science Sun and from time to time for Zhifei Biopharma, to monitor the progress of product development or achievement of commercialization performance targets. Source: Luzhu Biotech-B (02480) Prospectus (IPO Date : 2023/04/25)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	KONG Jian & Associates (Total share: 45.90%); (H share: 45.90%) Beijing E-town Sun Fund Management Co., Ltd. (Total share: 18.89%); (H share: 18.89%) Beijing Yizhuang II Biological Medical Industry Investment Fund (Total share: 9.12%); (H share: 9.12%) Beijing Science Sun Pharmaceutical Co., Ltd. (Total share: 6.84%); (H share: 6.84%) [00939] China Construction Bank Corporation (Total share: 5.79%); (H share: 5.79%)
Directors	KONG Jian (Chairman and General Manager and Chief Scientific Officer and Executive Director) JIANG Xianmin (Vice Chairlady and Deputy General Manager and Chief Medical Officer and Executive Director) ZHANG Yanping (Deputy General Manager and Executive Director) KONG Shuangquan (Non-Executive Director) MA Biao (Non-Executive Director) HOU Aijun (Independent Non-Executive Director) LEUNG Wai Yip (Independent Non-Executive Director) LIANG Yeshi (Independent Non-Executive Director)
Company Secretary	LIU Siyu YUEN Wing Yan, Winnie
Principal Bankers	Agricultural Bank of China Limited China Construction Bank
Solicitors	Eric Chow & Co. in Association with Commerce & Finance Law Offices Commerce & Finance Law Offices
Auditors	Deloitte Touche Tohmatsu
Registered Office	5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	http://www.luzhubiotech.com
Email Address	IR@luzhubiotech.com
Tel No	(86 010) 6156-8561
Fax No	(86 010) 6156-7093

SITEMAP

AASTOCKS.com

Members

Forgot Password

About Us

Email: support@aastocks.com

AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.

Disclaimer

You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.